A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study [0.03%]
DRAGON研究：在亚洲慢性偏头痛患者中进行的评估erenumab预防治疗效果的III期、随机、安慰剂对照研究
Shengyuan Yu,Byung-Kun Kim,Hebo Wang et al.
Shengyuan Yu et al.
Abstact: BACKGROUND: DRAGON was a phase 3, randomised, double-blind, placebo-controlled study which evaluated the efficacy and safety of erenumab in patients with chronic migraine (CM) from Asia not adequately represented...
Genome-wide analyses identify novel risk loci for cluster headache in Han Chinese residing in Taiwan [0.03%]
全基因组分析鉴定出台湾汉族人群丛集性头痛的新风险位点
Shih-Pin Chen,Chia-Lin Hsu,Yen-Feng Wang et al.
Shih-Pin Chen et al.
Background: Cluster headache is a highly debilitating neurological disorder with considerable inter-ethnic differences. Genome-wide association studies (GWAS) recently identified replicable genomic loci for cluster headac...
Microvascular decompression in trigeminal neuralgia - a prospective study of 115 patients [0.03%]
三叉神经痛中微血管减压术的前瞻性研究
Anne Sofie Schott Andersen,Tone Bruvik Heinskou,Per Rochat et al.
Anne Sofie Schott Andersen et al.
Background: Trigeminal neuralgia is a severe facial pain disorder. Microvascular decompression is first choice surgical treatment of patients with classical TN. There exist few prospective studies with an independent eval...
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results [0.03%]
瑞士真实世界依瑞奈尤单抗治疗偏头痛患者生活质量及医疗保健影响评估（SQUARE研究）：期中结果
Andreas R Gantenbein,Reto Agosti,Christian P Kamm et al.
Andreas R Gantenbein et al.
Background: The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine. To compleme...
Observational Study
The journal of headache and pain. 2022 Nov 18;23(1):142. DOI:10.1186/s10194-022-01515-8 2022
Comment regarding: what is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta‑analysis of clinical trials [0.03%]
评论主题：有氧运动与力量训练在偏头痛治疗中的疗效对比？一项临床试验的系统评价和网络meta分析
Junhee Han,Soo-Jin Cho
Junhee Han
In Woldeamanuel and Oliveira (2022)'s article about the efficacy of exercise in the treatment of migraine, the ranking of the efficacy of strength training (mean difference, - 3.55), aerobic exercise (mean difference, - 2.18 to - 3.13), top...
Enhanced pain facilitation rather than impaired pain inhibition in burning mouth syndrome female patients [0.03%]
患有灼口综合征的女性患者是促进疼痛而不是抑制疼痛的能力增强
Christelle Gremeau-Richard,Paul Pionchon,Aurélien Mulliez et al.
Christelle Gremeau-Richard et al.
Background: Deficient endogenous pain modulation has been implicated in the development and exacerbation of chronic orofacial pain. To date, relatively little is known regarding the function of the endogenous pain modulat...
Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study [0.03%]
艾瑞努单抗与托吡酯的对比：来自HER-MES研究的实效事后分析
Marc Ehrlich,Christian Hentschke,Christian Sieder et al.
Marc Ehrlich et al.
Objective: HER-MES was the first head-to-head, phase 4 trial to assess the tolerability and effectiveness of erenumab against standard of care treatment (topiramate). This post hoc analysis compared the efficacy of erenum...
Randomized Controlled Trial
The journal of headache and pain. 2022 Nov 15;23(1):141. DOI:10.1186/s10194-022-01511-y 2022
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency [0.03%]
偏头痛的先兆症状：一项关于报道发生率或相对频率的观察性研究的系统回顾和荟萃分析
Anna K Eigenbrodt,Rune Häckert Christensen,Håkan Ashina et al.
Anna K Eigenbrodt et al.
Background: Observational studies on the prevalence of premonitory symptoms in people with migraine, preceding the headache pain (or aura) phase, have shown conflicting results. We conducted a systematic review and meta-a...
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis [0.03%]
Erenumab对难治性慢性偏头痛的两年疗效：一项前瞻性的实际分析
Anna P Andreou,Matteo Fuccaro,Bethany Hill et al.
Anna P Andreou et al.
Background: Controlled and real-world evidence have demonstrated the efficacy of calcitonin gene related peptide (CGRP) monoclonal antibodies (MABs) in migraine. However, data on the over-one-year sustained effectiveness ...
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients [0.03%]
针对偏头痛患者的抗CGRP单克隆抗体反应预测因素：一项关于864例偏头痛患者的研究
Piero Barbanti,Gabriella Egeo,Cinzia Aurilia et al.
Piero Barbanti et al.
Background and objectives: The identification of predictors of response to antiCGRP mAbs could favor tailored therapies and personalized treatment plans. This study is aimed at investigating predictors of ≥ 50%, ≥ 75% a...
Multicenter Study
The journal of headache and pain. 2022 Nov 1;23(1):138. DOI:10.1186/s10194-022-01498-6 2022